title: [Joint Statement of the German Society for Digestive and Metabolic Diseases (DGVS), the German Society for Neurogastroenterology and motility (DGNM) and the German Society for Internal Medicine (DGIM) for linaclotide-benefit assessment of the Institute for Quality and Efficiency in Health Care (IQWiG) in accordance with § 35a SGB V (dossier evaluation)].
authors.forename: V
authors.initials: V
authors.lastname: Andresen
authors.forename: P
authors.initials: P
authors.lastname: Layer
mesh_terms: D003248:Constipation / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology; D005762:Gastroenterology / Q000592:standards*; D005858:Germany; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D010455:Peptides; C523483:linaclotide